Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Corey Cutler, MD MPH, FRCPC, Stephanie J. Lee, MDMPH, Sally Arai, MD MS, Marcello Rotta, MD, Behyar Zoghi, MD, Aravind Ramakrishnan, MD, David Eiznhamer, PhD, Olivier Schueller, PhD, Zhongming Yang, PhD, Laurie S. Green, MD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Steven Z. Pavletic, MD MS, Madan Jagasia, MBBS, MS, MMHC

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139445

Published: 2020

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

Surya S Kotha, Kiet T Phong, Amie Adams, Brian Hayes, PhD, Meredith A Roberts, Karol Bomsztyk, MD, Aravind Ramakrishnan, MD, Beverly Torok-Storb, PhD, Ying Zheng, PhD

Blood (2015) 126 (23): 3602.

https://doi.org/10.1182/blood.V126.23.3602.3602

Published: 2015

Journal Articles

U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies

Janine O. Ilagan, PhD, Aravind Ramakrishnan, MD, Brian Hayes, PhD, Michele E. Murphy, Ahmad S. Zebari, Philip Bradley, PhD, Robert K. Bradley, PhD

Blood (2014) 124 (21): 1889.

https://doi.org/10.1182/blood.V124.21.1889.1889

Published: 2014

Journal Articles

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Eunhee Kim, PhD, Janine O. Ilagan, PhD, Stanley Lee, PhD, Aravind Ramakrishnan, MD, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Michele E. Murphy, Min-Kyung Kim, BS, Ahmad S. Zebari, Jacob Feala, Silvia Buonamici, PhD, Peter G Smith, PhD, H. Joachim Deeg, MD, Camille Lobry, PhD, Iannis Aifantis, PhD MSC, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 824.

https://doi.org/10.1182/blood.V124.21.824.824

Published: 2014

Journal Articles

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Aaron L. Holsinger, Aravind Ramakrishnan, MD, Barry Storer, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, H. Joachim Deeg, MD, Bart L. Scott, MD

Blood (2007) 110 (11): 1452.

https://doi.org/10.1182/blood.V110.11.1452.1452

Published: 2007

NARROW

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only